Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing

Data ReadoutpositiveERNA-201ERNA-101Positive

AI Analysis

Summary

Ernexa Therapeutics reported positive preclinical data for ERNA-201 demonstrating disease-modifying activity in a collagen-induced arthritis model, validating its engineered synthetic iMSC platform. The company is advancing ERNA-101 toward first-in-human dosing while accelerating its oncology strategy.

Clinical Trial Data

Phase

Preclinical

Primary Endpoint

Met

Outcome Details

ERNA-201 demonstrated encouraging disease-modifying activity in collagen-induced arthritis model

Importance:5/10

Sentiment:

0.70

preclinical datadisease-modifyingiMSC platformoncologyrheumatoid arthritisfirst-in-human

Related Companies

$ERNAW

Read the original article

Published by GlobeNewswire Clinical Studies on September 15, 2026 12:42 PM

Read Original